Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)

NCT04750343 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

328

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 (Healthy Volunteers)

Interventions

BIOLOGICAL: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1
BIOLOGICAL: GBP510 (RBD 10μg/dose) - Stage 1
OTHER: Normal saline (0.9% sodium chloride solution) - Stage 1
BIOLOGICAL: GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1
BIOLOGICAL: GBP510 (RBD 25μg/dose) - Stage 1
OTHER: Normal saline (0.9% sodium chloride solution) - Stage 1
BIOLOGICAL: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2
BIOLOGICAL: GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2
BIOLOGICAL: GBP510 (RBD 25μg/dose)- Stage 2
OTHER: Normal saline (0.9% sodium chloride solution)- Stage 2

Sponsor

SK Bioscience Co., Ltd.

Collaborators

[object Object]
[object Object]